The Jackson Laboratory

University of Massachusetts

James Keck

Chunting Ye

Leonard D Shultz

Dale L Greiner

Michael A Brehm

Jing Jiao

Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.

Method of determining toxicity of an immunomodulatory drug for use in humans

A method of identifying anti-tumor activity of a test substance is provided along with a genetically-modified, immunodeficient mouse and methods of use, wherein the genetically-modified, immunodeficient mouse enables in vivo investigation of the interactions between the human immune system and human cancer.

Methods and models for assessing efficacy of immunotherapies

Provided herein are humanized mouse models and methods for determining whether administration of engineered immune cell therapies likely elicit cytokine release syndrome and/or determining the efficacy of an anti-disease therapy. Further, the models provided herein may be used to test the efficacy of different anti-CRS therapies.

Humanized mouse models for assessing immune cell therapy

Method of determining toxicity of an immunomodulatory drug for use in humans preliminary class

The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.

Growing community of inventors

Sacramento, CA, United States of America

James Keck